{"entities":{"Q110983":{"pageid":112456,"ns":120,"title":"Item:Q110983","lastrevid":59677902,"modified":"2026-04-10T13:32:00Z","type":"item","id":"Q110983","labels":{"en":{"language":"en","value":"Issues in designing sequential stopping rules for monitoring side effects in clinical trials"}},"descriptions":{"en":{"language":"en","value":"scientific article"}},"aliases":{},"claims":{"P31":[{"mainsnak":{"snaktype":"value","property":"P31","hash":"fd5912e4dab4b881a8eb0eb27e7893fef55176ad","datavalue":{"value":{"entity-type":"item","numeric-id":56887,"id":"Q56887"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q110983$1A00193F-17D6-4F96-BA99-2E0DF13A242A","rank":"normal"}],"P200":[{"mainsnak":{"snaktype":"value","property":"P200","hash":"a31ad642f0d347c42266634c66f56e4b5181049a","datavalue":{"value":{"entity-type":"item","numeric-id":60781,"id":"Q60781"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q110983$0C7654A0-D42C-4EDD-B2C0-73477CE147D3","rank":"normal"}],"P26":[{"mainsnak":{"snaktype":"value","property":"P26","hash":"e774021f6923ba4d7b1138251177d9e557216701","datavalue":{"value":"8","type":"string"},"datatype":"string"},"type":"statement","id":"Q110983$F2C406F5-ADCC-4076-82EA-8534F5E96106","rank":"normal"}],"P25":[{"mainsnak":{"snaktype":"value","property":"P25","hash":"133c4f1f6faefb140213d67b06b427618fdbf331","datavalue":{"value":"4","type":"string"},"datatype":"string"},"type":"statement","id":"Q110983$46A31845-FDA6-4C36-84E3-18B5D62F0E62","rank":"normal"}],"P128":[{"mainsnak":{"snaktype":"value","property":"P128","hash":"98433842eb72125b7e0d1edf6561be4a6a92155d","datavalue":{"value":"327-337","type":"string"},"datatype":"string"},"type":"statement","id":"Q110983$05474C69-E1C4-4CD9-A2FE-1226D6B8A83E","rank":"normal"}],"P28":[{"mainsnak":{"snaktype":"value","property":"P28","hash":"03c8bc0305b3681598b8ecc47cff52dd2697fc3b","datavalue":{"value":{"time":"+1987-12-00T00:00:00Z","timezone":0,"before":0,"after":0,"precision":10,"calendarmodel":"http://www.wikidata.org/entity/Q1985727"},"type":"time"},"datatype":"time"},"type":"statement","id":"Q110983$A28B1495-DED8-426C-9E87-4BA497B61645","rank":"normal"}],"P16":[{"mainsnak":{"snaktype":"value","property":"P16","hash":"95a579abd3881dfedcc7190646860b1850f18c4b","datavalue":{"value":{"entity-type":"item","numeric-id":110982,"id":"Q110982"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q110983$FB50D2F5-7BA4-4927-91FE-3D5EFF966FE0","rank":"normal"}],"P12":[{"mainsnak":{"snaktype":"value","property":"P12","hash":"9b95a8a62aeabe543f8ea669d16d1807ce4e17b9","datavalue":{"value":"Q51657585","type":"string"},"datatype":"external-id"},"type":"statement","id":"Q110983$CBD466B6-9CCA-4B0D-BBB8-2A622CE8B66F","rank":"normal"}],"P1460":[{"mainsnak":{"snaktype":"value","property":"P1460","hash":"57f7fea50d2ce1b39b695c4a1313582eed405e38","datavalue":{"value":{"entity-type":"item","numeric-id":5976449,"id":"Q5976449"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q110983$55697F72-4766-498E-832B-7D801468FAD7","rank":"normal"}],"P27":[{"mainsnak":{"snaktype":"value","property":"P27","hash":"5ffb733745372b5094c30a963886ece8d0a82095","datavalue":{"value":"10.1016/0197-2456(87)90153-X","type":"string"},"datatype":"external-id"},"type":"statement","id":"Q110983$E6D57906-E5F9-4754-B210-B8F1A4D061F8","rank":"normal"}]},"sitelinks":{"mardi":{"site":"mardi","title":"Issues in designing sequential stopping rules for monitoring side effects in clinical trials","badges":[],"url":"https://portal.mardi4nfdi.de/wiki/Issues_in_designing_sequential_stopping_rules_for_monitoring_side_effects_in_clinical_trials"}}}}}